HongKong:2359

WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time

* Revenue Up 2.5% Year-over-Year to RMB40,341 Million; Excluding COVID-19 Commercial Projects, Up 25.6% * Net Profit Attributable to the Owners of the Company[1] Increased 9.0% to RMB9,607 Million; Diluted Earnings per Share (EPS) Increased 14.9% to RMB3.24 * Adjusted Non-IFRS Net Profit Att...

2024-03-18 20:32 1877

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma

AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval fora solid tumor cancer. PHILADELPHIA, Feb. 20, 2024 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Drug Admini...

2024-02-20 21:00 2697

WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site

Expansion Boosts Solid-Phase Peptide Synthesis Total Reactor Volume to 32,000 Liters in Response to Surging Demand SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, b...

2024-01-08 22:00 4498

WuXi AppTec Named 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year by Frost & Sullivan

SHANGHAI, Nov. 8, 2023 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, recei...

2023-11-09 08:00 1505

WuXi AppTec Continued Solid Growth in the First Three Quarters of 2023 on Top of an Exceptionally Strong Year in 2022, with Profit Growth Continuously Exceeding Revenue Growth

* Revenue of RMB10,670 Million in the Third Quarter, Single Quarter Revenue Back to overRMB10 Billion; Revenue of RMB29,541 Million in the First Three Quarters, Up 4.0% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 23.4% * Net Profit Attributable to Owners of the Company for the ...

2023-10-30 20:01 2041

WuXi AppTec Announced Strong Results of the Second Quarter and First Half of 2023, on Top of an Exceptionally Strong Year in 2022

* Revenue of RMB9,908 Million in the Second Quarter, Up 6.7% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 39.5% * Revenue of RMB18,871 Million in the First Half, Up 6.3% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 27.9% * Net Profit Attributable to Owners of the Co...

2023-07-31 18:02 3707

WuXi AppTec Continued Solid Growth in First-Quarter of 2023 On Top of an Exceptionally Strong Year of 2022

Revenue Up 5.8% Year-Over-Year to RMB8,964 Million Net Profit Attributable to Owners of the Company Up 32.0% Year-Over-Year to RMB2,168 Million Diluted Earnings per Share (EPS) Up 35.8% Year-Over-Year to RMB0.72 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 14.1% Year-Over-...

2023-04-24 18:03 2066

WuXi AppTec Named to the 2022 Dow Jones Sustainability World Index

SHANGHAI, Dec. 20, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, today announced that it has been included in the 2022 Dow Jones Sustainability™ World Index (DJSI). This demonstrates th...

2022-12-21 08:00 2028

WuXi AppTec Receives 2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan

SHANGHAI, Nov. 29, 2022 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services for the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, announced that it is a r...

2022-11-30 08:00 2070

WuXi AppTec Reports Record Year-to-Date Results in 2022, Third Quarter Revenue over RMB10 Billion

Revenue Up 71.9% Year-Over-Year to RMB28,395 Million Net Profit Attributable to Owners of the Company Up 107.1% Year-Over-Year to RMB7,378 Million Diluted Earnings Per Share (EPS) Up 90.1% Year-Over-Year to RMB2.30 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 77.9% Year...

2022-10-26 19:06 3144

WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility

New facility expands integrated drug product R&D and manufacturing services to global customers SHANGHAI, Sept. 26, 2022 /PRNewswire/ -- WuXi STA, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of its first high potency (HP) o...

2022-09-26 20:00 1370

WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers

SHANGHAI, Sept. 9, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus. Created in response to the increasing demand for complex injection dosag...

2022-09-09 20:00 1458

WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware

MIDDLETOWN, Del., Aug. 16, 2022 /PRNewswire/ -- WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus inMiddletown, Delaware. First announced in June 2021, this...

2022-08-17 01:47 4059

WuXi ATU Announces Licensing Agreement with Janssen for TESSA™ Technology

PHILADELPHIA, Aug. 11, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced a licensing agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen"). Under this agreement, WuXi ATU ...

2022-08-12 09:09 1745

WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility

Site Enhances New Modality CRDMO Platform Capacity for Customers SHANGHAI , July 6, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at itsChangzhou campus. The new facility underscores...

2022-07-07 08:00 3409

WuXi AppTec Reports Record First-Quarter In 2022

Revenue Up 71.2% Year-Over-Year to RMB8,474 Million Net Profit Attributable to Owners of the Company Up 9.5% Year-Over-Year to RMB1,643 Million Diluted Earnings Per Share (EPS) Up 3.9% Year-Over-Year to RMB0.53 Adjusted Non-IFRS[1] Net Profit Attributable to Owners of the Company Up 85.8% Ye...

2022-04-25 17:52 2457

WuXi ATU Announces Launch of TESSA™ Technology to Improve Scalability and Accessibility of Cell and Gene Therapies

PHILADELPHIA, March 7, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™). This technology is a state-of-the-art novel process for transfection-free, scalable manu...

2022-03-08 08:00 1312

Statement by WuXi AppTec Regarding Recent Market Fluctuation

SHANGHAI, Dec. 15, 2021 /PRNewswire/ -- Our company's activities continue apace and we remain confident in our platform, which enables our global customers and serves patients around the world. We will provide any new information as warranted and in compliance with applicable laws and regulations...

2021-12-16 08:00 2262

WuXi AppTec Receives 2021 Global Customer Value Leadership Award from Frost & Sullivan

SHANGHAI, Dec. 8, 2021 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, announced that it is a recipient of the 2021 Global CRDMO Customer Value Leadership Award from Frost & Sullivan, a global ...

2021-12-09 08:00 1831

WuXi AppTec Receives AA ESG Rating from MSCI

SHANGHAI, Sept. 5, 2021 /PRNewswire/ -- WuXi AppTec ("the Company") is pleased to announce that Morgan Stanley Capital International ("MSCI") has upgraded its MSCI ESG Rating to AA. The Company also received outstanding scores in the areas of "corporate governance" and "product safety and quality...

2021-09-06 08:00 2229
12

Week's Top Stories